Verition Fund Management
BCRX icon

Verition Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Verition Fund Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-57,451
Closed -$436K – 3515
2025
Q3 		$436K Buy
57,451
+35,555
+162% +$296K ﹤0.01% 3104
2025
Q2 		$196K Sell
21,896
-47,964
-69% -$447K ﹤0.01% 3369
2025
Q1 		$524K Buy
69,860
+15,414
+28% +$124K ﹤0.01% 2565
2024
Q4 		$409K Buy
54,446
+14,926
+38% +$113K ﹤0.01% 2591
2024
Q3 		$300K Sell
39,520
-102,839
-72% -$782K ﹤0.01% 2643
2024
Q2 		$880K Buy
+142,359
New +$786K ﹤0.01% 1748
2024
Q1 		– Sell
-31,510
Closed -$189K – 2771
2023
Q4 		$189K Sell
31,510
-17,470
-36% -$101K ﹤0.01% 2054
2023
Q3 		$347K Buy
48,980
+18,300
+60% +$131K ﹤0.01% 1640
2023
Q2 		$216K Buy
30,680
+8,400
+38% +$67.4K ﹤0.01% 1794
2023
Q1 		$186K Buy
+22,280
New +$214K ﹤0.01% 1787
2022
Q2 		– Sell
-15,513
Closed -$252K – 2366
2022
Q1 		$252K Buy
+15,513
New +$249K ﹤0.01% 2233
2021
Q3 		– Sell
-14,634
Closed -$231K – 1904
2021
Q2 		$231K Buy
+14,634
New +$199K ﹤0.01% 1491
2020
Q4 		– Sell
-541,839
Closed -$1.86M – 1101
2020
Q3 		$1.86M Buy
+541,839
New +$2.32M 0.04% 273

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Verition Fund Management's BCRX Position: Q4 2025 in Review

Verition Fund Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 57,451 shares — an estimated $436K sold.

Verition Fund Management first reported a position in BCRX in Q3 2020 and held it in 13 quarters. The position peaked at $1.86M in Q3 2020. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Verition Fund Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 57,451 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $436K.
  • Verition Fund Management first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 13 quarters.
  • Verition Fund Management's BioCryst Pharmaceuticals position peaked at $1.86M in Q3 2020.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.